Proliferative vs non-proliferative diabetic retinopathy in CKD patients is associated with a higher risk of CKD progression.
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Suppressing albuminuria should be an important target of therapy, according to investigators.
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
Additional focus on lifestyle management, self-management education and support emphasized
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.